Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 254

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1C
Chunk 254
---
 filed subsequent to the completion of the initial Business Combination and rights to require the Company to
register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement will
provide that the Company will not be required to effect or permit any registration or cause any registration statement to become effective
until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such
registration statements.

Underwriting Agreement

The Company granted the underwriters a 45-day
option from the date of the final prospectus, January 27, 2025, to purchase up to 3,000,000 additional Units to cover over-allotments,
if any, at the Initial Public Offering price less the underwriting discounts and commissions. On February 18, 2025, the underwriters exercised
their option in full, to purchase an additional 3,000,000 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds
of $30,000,000.

The underwriters were entitled to a cash underwriting
discount of $0.05 per Unit, or 0.5% of the gross proceeds of the Initial Public Offering, or $1,000,000 in the aggregate (or up to $1,150,000
if the over-allotment option is exercised in full), paid at the closing of the Initial Public Offering and the $150,000 was paid on the
closing of the over-allotment option. In addition, the underwriters are entitled to a deferred fee of $0.30 per Unit, or 3.0% of
the gross proceeds of the Initial Public Offering, or $6,900,000 in the aggregate, of which 25.0% will be adjusted net of redemptions
(i.e., for purposes of calculating the deferred underwriting commission net of redemptions, 25.0% of the deferred underwriting commissions
will determined by the dollar amount that is product of (i) 3.0% multiplied by the product of the number of unredeemed public shares,
multiplied by $10.00 and (ii) 25.0%). The deferred fee becomes payable to the underwriters from the amounts held in the Trust Account
solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition,
the Company agreed to issue the underwriters 230